Improved prognosis of diffuse histiocytic and undifferentiated lymphoma by use of high dose methotrexate alternating with standard agents (M-BACOD).
Improved prognosis of diffuse histiocytic and undifferentiated lymphoma by use of high dose methotrexate alternating with standard agents (M-BACOD).
复制标题
通过交替使用高剂量甲氨蝶呤和标准药物 (M-BACOD)，改善弥漫性组织细胞和未分化淋巴瘤的预后。
DOI：
10.1200/jco.1983.1.2.91
复制
发表时间：
1983
期刊：
影响因子：
--
通讯作者：
E. Frei
中科院分区：
文献类型：
--
作者：
A. Skarin;G. Canellos;D. Rosenthal;D. Case;J. Macintyre;G. Pinkus;W. Moloney;E. Frei
采用新的联合化疗方案（M-BACOD）治疗101例晚期弥漫性组织细胞和弥漫性未分化淋巴瘤（DHL和DUL）。在博来霉素（B）、阿霉素（A）、环磷酰胺（C）、长春新碱（O）和地塞米松（D）每3周一次给药的周期之间的第14天给予高剂量甲氨蝶呤（M）3 g/m2和甲酰四氢叶酸因子补救，共10个周期。101例患者的完全缓解率（CR）为72%，95例可评价患者的CR为77%。中位随访时间为3年2个月，三分之一的CR患者随访超过4年。26%的CR患者复发，预计5年生存率为80%（5年无病率为65%）。所有101例研究患者的总生存率达到59%的平台期，预计到5年。既往接受过治疗的患者的CR率显著低于既往未接受过治疗的患者（p = 0.001）;然而，未发现其他不良预后特征。仅5.4%的CR患者发生中枢神经系统CNS复发。M-BACOD可延长所有DHL和DUL患者的生存期并可能治愈。
A new combination chemotherapy program (M-BACOD) was administered to 101 patients with advanced diffuse histiocytic and diffuse undifferentiated lymphoma (DHL and DUL). High dose methotrexate (M) 3 g/m2 with leucovorin factor rescue was given on day 14 between cycles of bleomycin (B), adriamycin (A), cyclophosphamide (C), oncovin (O), and dexamethasone (D) administered every 3 weeks for 10 cycles. The complete remission rate (CR) was 72% in all 101 patients or 77% in 95 evaluable patients. The median follow-up is 3 yr 2 mo with one-third of CR patients followed beyond 4 yr. Twenty-six percent of CR patients have relapsed with a projected 5-yr survival rate of 80% (5-yr disease-free rate 65%). The overall survival of all 101 study patients reaches a plateau at 59% projected out to 5 yr. Patients with prior therapy had a significantly lower CR rate than those without prior treatment (p = 0.001); however, no other unfavorable prognostic characteristics could be identified. Relapse in the central nervous system CNS occurred in only 5.4% of CR patients. M-BACOD results in prolonged survival and possible cure in a high proportion of all patients with DHL and DUL.
影响因子：
11.2
作者：
P. Carbone;H. Kaplan;K. Musshoff;D. Smithers;M. Tubiana
通讯作者：
P. Carbone;H. Kaplan;K. Musshoff;D. Smithers;M. Tubiana